Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Cocaine-Related Disorders · Cocaine Dependence · DRUG

BRIGHT MINDS BIOSCIENCES

BRIGHT MINDS BIOSCIENCES INC.

BRIGHT MINDS BIOSCIENCES clinical programs — 1063 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
19 Vestry St, New York, NY 10013, US HQ
12 Employees
Public company Type
DRUG · NYSE Ticker
Company details
Status
Public
HQ
19 Vestry St, New York, NY 10013, US
Employees
12
Programs
1063
Drugs
444
Patents
57
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

BRIGHT MINDS BIOSCIENCES projects

1,063 ClinicalTrials.gov programs sponsored by BRIGHT MINDS BIOSCIENCES.

BRIGHT MINDS BIOSCIENCES has 1,063 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

1,063 programs

Clinical programs

Page 9 of 23

  1. PF-05190457

    BRIGHT MINDS BIOSCIENCES INC.

    Alcoholism

    phase 2 small molecule terminated

    1 trial

  2. PIO

    BRIGHT MINDS BIOSCIENCES INC.

    Heroin Dependence

    phase 2 small molecule terminated

    1 trial

  3. PPRS

    BRIGHT MINDS BIOSCIENCES INC.

    Drug Use

    phase 2 other completed

    1 trial

  4. Panitumumab

    BRIGHT MINDS BIOSCIENCES INC.

    Advanced Head and Neck Squamous Cancer

    phase 2 small molecule completed

    1 trial

  5. Parenting in 2 Worlds (P2W)

    BRIGHT MINDS BIOSCIENCES INC.

    Parenting

    phase 2 other active

    1 trial

  6. Pemoline

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    2 trials

  7. Pepinemab

    BRIGHT MINDS BIOSCIENCES INC.

    Alzheimer Disease

    phase 2 small molecule completed

    1 trial

  8. Perindopril

    BRIGHT MINDS BIOSCIENCES INC.

    Alzheimer's Disease

    phase 2 small molecule terminated

    1 trial

  9. Pioglitazone

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Use Disorder

    phase 2 small molecule completed

    1 trial

  10. Placebo

    BRIGHT MINDS BIOSCIENCES INC.

    Methamphetamine Dependence

    phase 2 small molecule completed

    2 trials

  11. Placebo

    BRIGHT MINDS BIOSCIENCES INC.

    Addiction

    phase 2 small molecule completed

    1 trial

  12. Placebo

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder

    phase 2 small molecule active

    1 trial

  13. Placebo

    BRIGHT MINDS BIOSCIENCES INC.

    Bipolar Depression

    phase 2 small molecule terminated

    1 trial

  14. Placebo + Inactive Marijuana (0% THC)

    BRIGHT MINDS BIOSCIENCES INC.

    Marijuana Use

    phase 2 small molecule completed

    1 trial

  15. Placebo capsules

    BRIGHT MINDS BIOSCIENCES INC.

    Pain Threshold

    phase 2 small molecule completed

    1 trial

  16. Placebo session 1, Aprepitant session 2

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule completed

    1 trial

  17. Placebos

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis

    phase 2 small molecule completed

    1 trial

  18. Prazosin

    BRIGHT MINDS BIOSCIENCES INC.

    Continuous Methamphetamine Abuse

    phase 2 small molecule completed

    1 trial

  19. Pre-Quit Nicotine Lozenges

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking Cessation

    phase 2 small molecule completed

    1 trial

  20. Progesterone

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Use

    phase 2 small molecule completed

    1 trial

  21. Progesterone

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    phase 2 small molecule completed

    1 trial

  22. Proleukin

    BRIGHT MINDS BIOSCIENCES INC.

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  23. Propranolol

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  24. Propranolol

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule completed

    2 trials

  25. Psilocybin

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder

    phase 2 small molecule active

    1 trial

  26. Psilocybin

    BRIGHT MINDS BIOSCIENCES INC.

    Healthy

    phase 2 small molecule completed

    1 trial

  27. Psilocybin

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    phase 2 small molecule active

    1 trial

  28. PvCS/Montanide ISA-51 VG Vaccine

    BRIGHT MINDS BIOSCIENCES INC.

    Plasmodium Vivax Malaria

    phase 2 mab active

    1 trial

  29. Quetiapine

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Dependence

    phase 2 small molecule completed

    1 trial

  30. QuitAdvisorMD Software Algorithm

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking

    phase 2 other active

    1 trial

  31. R01DA029050

    BRIGHT MINDS BIOSCIENCES INC.

    Drug Abuse

    phase 2 other completed

    1 trial

  32. Ramelteon

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    phase 2 small molecule completed

    1 trial

  33. Real cTBS

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 other completed

    1 trial

  34. Recombivax

    BRIGHT MINDS BIOSCIENCES INC.

    Hepatitis B

    phase 2 mab completed

    1 trial

  35. Recovery Line Support System

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-Related Disorders

    phase 2 other completed

    1 trial

  36. Recovery by Choice

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    phase 2 other completed

    1 trial

  37. Reserpine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  38. Residential

    BRIGHT MINDS BIOSCIENCES INC.

    Usual Aftercare

    phase 2 other completed

    1 trial

  39. Rimonabant

    BRIGHT MINDS BIOSCIENCES INC.

    Schizophrenia

    phase 2 small molecule terminated

    1 trial

  40. Risperidone

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule terminated

    6 trials

  41. Ritanserin

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  42. Rotigotine Transdermal System [Neupro]

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    phase 2 small molecule active

    1 trial

  43. SD-101 dermal cream (6%)

    BRIGHT MINDS BIOSCIENCES INC.

    Epidermolysis Bullosa

    phase 2 small molecule terminated

    1 trial

  44. SL-BUP

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder (OUD)

    phase 2 small molecule active

    1 trial

  45. SU2C-001

    BRIGHT MINDS BIOSCIENCES INC.

    Previously Treated Metastatic Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  46. Sativex

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Dependence

    phase 2 small molecule completed

    1 trial

  47. SelG1

    BRIGHT MINDS BIOSCIENCES INC.

    Sickle Cell Disease

    phase 2 small molecule completed

    1 trial

  48. Selegiline

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    3 trials

Frequently asked questions

How many clinical projects does BRIGHT MINDS BIOSCIENCES have?

1,063 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.